TAF1 is altered in 6.76% of melanoma patients [3].

TAF1 is an inclusion criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains TAF1 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [4].

TAF1 is altered in 4.48% of non-small cell lung carcinoma patients [3].

TAF1 is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TAF1 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

TAF1 is altered in 3.99% of colorectal carcinoma patients [3].

TAF1 is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TAF1 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

TAF1 is altered in 3.85% of glioblastoma patients [3].

TAF1 is an inclusion criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains TAF1 status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [4].

TAF1 is altered in 3.15% of malignant solid tumor patients [3].

TAF1 is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains TAF1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [4].

TAF1 is altered in 2.59% of pancreatic carcinoma patients [3].

TAF1 is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TAF1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

TAF1 is altered in 2.26% of ovarian carcinoma patients [3].

TAF1 is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TAF1 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

TAF1 is altered in 2.17% of bladder carcinoma patients [3].

TAF1 is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TAF1 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

TAF1 is altered in 2.51% of breast carcinoma patients [3].

TAF1 is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TAF1 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

TAF1 is altered in 1.2% of head and neck carcinoma patients [3].

TAF1 is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TAF1 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

TAF1 is altered in 1.09% of sarcoma patients [3].

TAF1 is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains TAF1 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

TAF1 is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains TAF1 status and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) [4].

TAF1 is an inclusion criterion in 1 clinical trial for lymphoma, of which 0 are open and 1 is closed. Of the trial that contains TAF1 status and lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].